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ABSTRACT 
 
Protein tyrosine phosphatase 1B (PTP1B) is a non-transmembrane protein 
implicated as negative regulator in the insulin and leptin pathways. PTP1B 
is also implicated in the development of breast cancer due to its 
dephosphorylating role on the proto-oncogene Src. During these years, 
PTP1B has emerged as a promising potential therapeutic target for the 
treatment of the type 2 diabetes. PTP1B control mechanisms are still 
controversial and not well understood. Here, I've contributed to identify a 
novel mechanism of regulation of PTP1B mediated by the ubiquitin-
proteasome pathway. We identify the E3 ligase praja2 as novel interactor 
and regulator of PTP1B. Thus, praja2 ubiquitinates PTP1B and sustains the 
insulin pathway, interfering with praja2 expression or activity negatively 
impacts on the insulin pathway. This different control mechanism of the 
insulin pathway through PTP1B ubiquitination adds a new dowel to the 
comprehension of the molecular basis of metabolic disorders.       
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1. Introduction 
 
 
cAMP and the Ubiquitin-Proteasome System (UPS) 
1.1 cAMP Signaling 
Second messengers has a pivotal role in the transduction signal in response 
to hormones and growth factors. Cyclic adenosine 3′-5′-monophosphate 
(cAMP) represents an ancient second messenger implicated in crucial 
biological function. cAMP levels, duration and amplitude of propagating 
signal are tightly regulated by different classes of enzymes: the adenylyl 
cyclases (ACs), the cyclic nucleotide phosphodiesterases (PDEs), protein 
kinases, phosphatases (PPs) and scaffold proteins. The main effector of 
cAMP is protein kinase A (PKA), whose role is fundamental in the 
propagation of the signal downstream to target substrates/effectors (1).  
cAMP is tightly linked to a large family of membrane proteins, G protein–
coupled receptors (GPCRs) which transduce the signal from the 
extracellular microenvironment to inside the cells (Rosenbaum et al., 
2009). GPCRs are a heterotrimeric complex composed by three sub unites, 
GαS, β and γ. Once the receptor is activated the α subunits is released from 
β/γ sub unites, so it can active the AC driving the formation of the cAMP 
(2). The activation of different isoforms of ACs are mediated by kinases, 
like PKA, PKC, Calmomodulin Kinase or Ca2+ (3, 4). 
One of the most important target of the cAMP is the Protein Kinase A 
(PKA). This protein is a tetramer composed by two regulatory subunits (R) 
and two catalytic subunits (C), the binding of the cAMP to the R subunits 
causes a conformational change to the holoenzyme that leads to 
dissociation of the C subunits, which are able to phosphorylates different 
substrates, controlling different aspects of cell physiology (5). Scaffold 
proteins, called A-kinase anchoring proteins (AKAPs), drive the 
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localization of PKA in the different compartments of the cells, close to its 
substrates(6). Each AKAP contains two important domains; one is 
implicated into the association to regulatory subunits of PKA, and the other 
is a targeting domain that directs the kinase to specific subcellular 
compartments (Fig.1). Biochemical and structural studies identified a 
conserved PKA-binding domain of AKAPs that forms an amphipathic 
helical wheel composed of 14–18- residues (7). The helical wheel binds 
with high affinity the N-terminal docking/dimerization (D/D) domain of 
the PKA-R dimer (8, 9). The assembled components of the cAMP such as, 
receptors, conjugated to the activation of AC, effectors, like AKAPs-PKA 
and attenuating enzymes like PDEs and PPs, lead to the formation of the 
transduceosome, thanks to which distinct signaling pathways converge and 
are locally attenuated or amplified, optimizing the biological response to 
extracellular stimuli (10-13). 
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                                                                                              Rinaldi et al. 2015 
 
Figure 1. Activation of cAMP signaling. Ligand-induced activation of GPCR 
dissociates Gαs subunit which in turn activates the adenylyl cyclase (AC) (14). 
AC converts ATP into cAMP. cAMP binds the regulatory subunits of PKA, which 
is anchored to AKAPs, and releases the catalytics subunits (C). The C subunits 
phosphorylate different PKA substrates (1). Protein phosphatases (PPs) 
contributes to attenuate and regulates the signal (4).       
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1.2 Ubiquitin-Proteasome System 
The ubiquitin–proteasome system (UPS) has emerged as an important 
control mechanism of cell metabolism, growth and survival. The UPS is 
the principal pathway to eliminate unneeded or damaged proteins (15). The 
ubiquitylation is mediated by the attachment of ubiquitin to the "γ-amine 
of lysine residues of target proteins. This process requires a series of ATP-
dependent enzymatic steps catalyzed by E1 (ubiquitinactivating), E2 
(ubiquitinconjugating), and E3 (ubiquitinligating) enzymes (16). E3-
ubiquitin ligases fall into two main classes characterized by a HECT 
domain or a RING domain (17, 18). HECT domain E3 ligases act 
catalytically to form a thioester intermediate during ubiquitin transfer to 
substrate, whereas RING E3 ligases attend as a scaffold that brings together 
the substrate and the E2 ligase. The result of this sequential cascade of 
events is the covalent attachment of ubiquitin molecules to lysine residues 
on the target protein. These modifications can involve either a single 
ubiquitin (mono-ubiquitylation) or a chain of ubiquitin (poly-
ubiquitylation (19) (Fig.2). Polyubiquitylation of substrates in many cases 
drives through proteasome degradation (15), but polyubiquitylated proteins 
can also follow a non-degradative pathway (20). This mechanism may 
control the intracellular trafficking of the target protein or its activity (21). 
The UPS can be reverted thanks to classes of proteins named 
deubiquitinates enzymes (DUBs), by removing the ubiquitin moieties to 
restore the localization/activity of the modified protein (20). 
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                                                                Copyright © www.emdbiosciences.com                   
Figure 2. Schematic representation of ubiquitin system. Several enzymes 
compose the ubiquitin proteasome system (UPS). E1, the ubiquitin activating 
enzyme, E2, the ubiquitin conjugating enzyme and the E3 ligase, which are 
specific for precise substrates and are responsible for associating the ubiquitin 
molecules to the substrates. After the action of these three enzymes, the 
ubiquitinates proteins are degraded via proteasome. The ubiquitinated proteins 
can be de-ubiquitinated by a specific DUBs enzyme. 
   
  
Interestingly, the cAMP-PKA signaling can regulate and be regulated by 
UPS at different steps, therefore controlling different aspects of cell fate. 
For example, the β-adrenergic receptor2 (β-2AR) can be desensitized 
thanks to UPS, indeed the adaptor protein ARRDC3 (arrestin domain 
containing 3) recruits the E3 ligase NEDD4 (neural precursor development 
down regulated protein 4) close to β-2AR. Concomitant inhibition of the 
deubiquitinase USP20 (Ubiquitin-specific-processing protease 20) by PKA 
favors ubiquitination and degradation of the receptor by NEDD4 (22, 23) 
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1.3 RING ligase praja2 
Praja1 and praja2 are two members of praja E3 ligase family, they share 
52.3% of sequence homology. The E3 ubiquitin ligase praja2 is a protein 
of 708 amino acids with an estimate weight of 78 kDa. However, there is a 
discrepancy between the praja2 estimate weight and the molecular mass 
show on SDS-polyacrylamide, infact praja2 is estimated to be 140 kDa 
(24). Praja2 is encoded by a gene localized on the long arm of the human 
chromosome 5 (5q21) (25). Praja1 is encoded by a gene mapped on human 
chromosome X encoding for a protein of 643 amino acids, with a molecular 
weight of 71 kDa (26). Booth proteins contain a well conserved domain at 
COOH-terminal end (aa 629-678), this domain is the RING-H2-finger 
motif. The RING-H2-finger motif is similar to the RING-finger motif, but 
with the substitution of the Cys4 replaced by His (27). Praja2 is 
characterized by a particular motif at the COOH terminal domain (aa583-
600), encoding an α-amphipathic helix. This domain is characteristic of 
AKAPs family proteins, fundamental for PKA anchoring   
 
 
 
Figure 3. Schematic representation of praja proteins. Praja1 is a protein of 643 
amino acids, while praja2 of 708 amino acids. They share 52.3% of sequence 
homology and, both, are characterized by a RING-H2 domain (in rose) and an α-
amphipathic helix (in yellow) at COOH-terminal. 
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It is demonstrated that, in mice, praja1 is important for the neuronal 
plasticity, which is significant for learning and memory (26). Praja1 is 
expressed in the basolateral complex of the amygdala during formation of 
the fear memory (28). Downregulation of praja2 levels are correlated, in 
rat, with axonal degeneration and neuronal cell death (25). It is 
demonstrated the crucial function of praja2 involved in the cAMP-
dependent signal transduction pathway. Praja2 controls the stability of 
mammalian regulatory subunits (R) of Protein Kinase A (PKA), regulating 
the strength and duration of the PKA signal output in response to cAMP, 
governing efficient nuclear cAMP signal and PKA-mediated long-term 
memory (29) (Fig.4). 
                                                                                       Lignitto et al. 2011 
Figure 4. Schematic representation of the role of praja2 in PKA signaling. 
Activation of the PKA by the ligand drives the dissociation of the catalytic sub-
unites (C) of the PKA holoenzyme from the regulatory (R) sub-unites which lead 
to the phosphorylation of Praja2 by the PKAc (C) sub-unites. Phosphorylates 
Praja2 is able to ubiquitinates and degrades R subunits through the proteasome 
pathway, with consequently accumulation of free active PKAc (C) sustaining the 
duration of cAMP signalling. 
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Praja2 is also involved in cAMP-induced neurite outgrowth, promoting 
proteasome degradation of NOGO-A, a crucial inhibitor of neurite 
outgrowth in mammalian brain (30) (Fig.5). 
 
                                                                                       Sepe et al. 2014 
Figure 5. Schematic model of Praja2-NOGO-A pathway. Under basal 
condition, NOGO-A regulates and inhibits neurite outgrowth. External stimuli, 
like BDNF or Forskolin (Fsk) activate the adenylate cyclase (AC), increasing the 
cAMP levels, dissociation from PKA holoenzyme of the catalytic sub-unites (C), 
triggering the phosphorylation of Praja2 which is able to ubiquitinate and degrade 
via UPS NOGO-A, promoting neurite outgrowth.  
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 Moreover, praja2 has a role in tumor growth, it controls the organ size and 
sustains glioblastoma growth in vivo, through the ubiquitination and 
degradation of MOB1, a core component of NDR/LATS kinase and a 
positive regulator of tumor-suppressor Hippo cascade (31) (Fig.6).  
                                                                                                             
Liginitto et al 2013 
Figure 6. praja2 schematic representation in the regulation of the Hippo 
pathway. MOB1 is ubiquitinated and degraded via proteasome by praja2. 
Degradation of MOB1 leads to the attenuation of LATS1/2 kinases activity, 
preventing phosphorylation and inactivation of YAP, which are able to enter in 
the nucleus, driving gene transcription, promoting cells proliferation and tumor 
growth.  
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A study demonstrates a markedly praja2 over-expression in differentiated 
thyroids cancer, high levels correlated with the malignant phenotype of the 
tumor (32). In addition, Praja2 is involved in the attenuation of the MAP 
kinases cascade, regulating the ubiquitination and degradation of a scaffold 
protein called KSR1, governing the maintenance of undifferentiated 
pluripotent state in mouse embryonic stem cells (33). Finally, a recent study 
revealed a role of Praja2 in the regulation of the insulin secretion in 
response to glucose stimulation. Praja2 ubiquitinates and degrades p35, 
activating calcium signaling and promoting insulin secretion (34).            
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1.4 Insulin Pathway 
 
Insulin biological effects are mediated by the binding of three highly 
homologous tyrosine kinase receptors, insulin, IGF-1 receptors (IR and 
IGF-1R) and the orphan insulin receptor-related receptor (IRR), which has 
been suggested to play a role in testis determination (35) and acts as an 
extracellular alkali sensor (36). Although insulin and IGF-1 preferentially 
bind to their own receptors, both ligands can also bind to the alternate 
receptor with reduced affinity (37). The IR, IGF-1R and IRR are tetrameric 
complex that consist in two α subunits, which are extracellular, and two 
transmembrane β subunits that are linked by disulfide bonds. The 
interactions between the hormones and the IR, IGF-1R lead to the 
activation of the pathway through a conformational change inducing the 
trans-phosphorylation of the β subunits further activating the kinase and 
allowing the recruitment of receptors substrates. A well known and 
characterized Insulin Receptors Substrates (IRSs) are a large family of 
proteins which act as scaffold to organize and mediate signaling complex 
(38) (39) (40-43) (44).  
PI3-kinase (PI3K) is the critical protein involved in the signaling pathway 
of the insulin metabolic action. The class Ia PI3-kinases are heterodimers 
composed by a regulatory and catalytic subunit, each of which occurs in 
several isoforms (45). PI3K, thanks to two SH2 domains in the regulatory 
subunits, bind to tyrosine-phosphorylated IRS proteins (44, 46) and this 
results in activation of the catalytic subunit, which rapidly phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2) in phosphatidylinositol 
(3,4,5)-triphosphate (PIP3) a crucial lipid second messenger. PI3K activity 
is reflected on a subset of AGC protein kinase family members, which 
includes isoforms of Protein Kinase B (Akt), 3-phosphoinositide-
dependent Protein Kinase 1(PDK-1), p70 ribosomal S6 Kinase (S6K), 
Serum and Gluco-Corticoid Induced Protein Kinase (SGK) and several 
isoforms of the Protein Kinase C (PKC) (Fig.7) 
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                                                                                                                        J. Boucher et al. 2014 
Figure 7. Insulin- and IGF-1-signaling pathways. Activation of the IR or IGF-
1 receptors by their ligands. Conformational change and autophosphorilations of 
the receptors leading to the recruitments of receptor substrates, such as IRSs and 
Shc proteins. Shc is necessary for the activation of the MAP kinase cascade, 
whereas IRSs proteins leading to the activation of Pi3K-PDK-AKT or PKC. AKT 
activation regulates most of insulin’s metabolic effects, such as glucose transport, 
cell cycle, lipid synthesis, gluconeogenesis, and glycogen synthesis.  
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PDK-1 is recruited under the plasma membrane binding PIP3 with a PH 
domain triggering its activation. PDK-1 phosphorylate and activate Akt in 
Thr-308, however, for a complete activation, Akt needs to be phosphorylate 
in Ser-473 by mammalian target of rapamycin complex 2 (mTORC2) (47-
49). The activation of Akt leads to the regulation of several pathways 
involved in metabolism, protein synthesis and cell growth. Infact the 
phosphorylation of tuberous sclerosis complex protein 2 (TSC2), mediated 
by Akt, causes the degradation of tumor suppressor complex, TSC1 and 
TSC2, which activates the mTORC1 complex. The inhibition of 4E-
binding protein 1 (4E-BP1), by phosphorylation from mTORC1 complex, 
activates ribosomal protein S6 kinase S6K1 and S6K2 and SREBP1, which 
regulates some genes associated to metabolism, protein synthesis and cell 
growth (50). 
Phosphoprotein Phosphatases play a pivotal role in the tight regulation of 
all the insulin action at different levels of the pathway. Cytoplasmic protein 
tyrosine phosphatases such as, PTP1B and transmembrane phosphatases, 
such as LAR, have been shown to dephosphorylate the tyrosine residues on 
activated IR and IGF-1R, as well as IRS proteins, thereby reducing their 
activity (51). Serine/threonine phosphatase proteins are also involved, 
PP2A is the main serine/threonine phosphatase in cells that regulates the 
activity of several kinases, involved in insulin action, including Akt, PKC, 
S6K, ERK, cyclindependent kinases, and IKK (52). 
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1.5 Metabolic regulation by Ubiquitin-Proteasome System  
Ubiquitin-Proteasome System has emerged as crucial regulation of several 
pathways involved in cell metabolism, growth and aging. Latest 
experimental evidence has described the pivotal role of the Ubiquitin-
Proteasome System (UPS) in the regulation of the insulin pathway. 
Consequently, UPS alterations are involved in metabolic diseases.  
Skeletal muscle is responsible for about 70–90% of insulin-stimulated 
glucose disposal (76, 77), on account of this, insulin resistance in skeletal 
muscle is the earliest step in the pathogenesis of metabolic syndrome and 
type 2 diabetes (78-80) That muscle-specific mitsugumin 53 (MG53) is an 
E3 ubiquitin-ligase tripartite motif-containing (TRIM) family protein and 
is specifically expressed in skeletal muscle and heart (81, 82). MG53 is 
involved in the insulin cascade; because, directly, regulates the insulin 
receptor and IRS1 protein stability through ubiquitin-dependent 
degradation (80). Animal models for insulin resistance and metabolic 
disorders show abundant MG53 overexpression after high-fat diet (HFD) 
(83-86). The upregulation of MG53 was also confirmed in obese humans 
(80), underling the link between MG53 and metabolic diseases. The 
overexpression of MG53 is tightly linked to the insulin resistance in 
skeletal muscle, instead ablation of MG53 in MG53-/- mice fed with HFD, 
does not display any decrease of the insulin receptor and IRS1 levels in 
skeletal muscle. 
The UPS is also involved in the regulation of the cellular growth played by 
the Cullin 7 (CUL7) E3 ubiquitin ligase complex containing the Fbw8-
substrate-targeting subunit, Skp1, and the ROC1 RING finger protein (87). 
A recent study shows the insulin receptor substrate 1 (IRS-1), as a 
proteolytic target of the CUL7 E3 ligase (87). CUL7 is a protein composed 
of 1700 amino acids which assemble a complex with Skp1, the Fbw8 F-
box protein and ROC1 (88-90), called SCF-like E3. The degradation of 
IRS-1 by CUL7 E3 ligase is a negative-feedback regulation by mTOR/S6K 
phosphorylations. IRS-1 is phosphorylated by S6K at Ser307 thanks to 
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which it can be ubiquitinated and degradated by the CUL7 E3 ubiquitin 
ligase complex (87). Genetic knock out of CUL7 leads cells to senescence, 
probably through sustained MAPK activation and/or increased Akt 
signaling (87, 91, 92).  
A recent study has described the regulation of insulin pathway, as a 
fundamental turning point for the balance between proteostasis and aging. 
The ubiquitin ligase CHIP plays a pivotal role in the cellular balance 
between protein folding and degradation (93-96). CHIP is fundamental for 
the ubiquitylation of damaged proteins relegated by chaperone partners to 
induce disposal through endocytic-lysosomal pathways (97, 98), 
proteasomal degradation (94-96), and autophagy (93). Riga et al study 
display the role of CHIP in the regulation of the ubiquitin-dependent 
degradation of the insulin receptor. Modulation of insulin signaling 
underlines a relationship between proteostasis and longevity (99). 
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1.6 Protein Tyrosine Phosphatase 1 B 
Protein tyrosine phosphatase 1B (PTP1B) is a non-transmembrane protein 
tyrosine phosphatase implicated in the regulation of several pathways. 
PTP1B is monomeric protein of 435 amino acid with an estimated weight 
of 50 kDa. It is characterized by three region; Catalytic phosphatase 
domain at the N-terminus (residues aa1–300), a regulatory region (resides 
aa 80-100) and a region (residues aa 400–435) that tethers the enzyme to 
the cytoplasmic face of the endoplasmic reticulum (ER) (57, 58). PTP1B 
is tightly regulated by four known mechanism, oxidation, phosphorylation, 
sumoylation and proteolysis (Fig.8). PTP1B activity is regulated in vivo by 
reversible oxidation involving Cys 215 at its active site, which temporarily 
abrogates its enzymatic activity (59). It is well known that the formation of 
transient ROS is generated by the activation of RTKs and integrin (59-61), 
PTP1B is regulated by both serine and tyrosine phosphorylation in multiple 
site, by several kinases such as protein kinase C (PKC) at S378 and at S352 
and S386 by an unknown kinase (62, 63), at S50 by AKT (64), CLK1 and 
CLK2 (65). The effects of phosphorylations are either modest or 
controversial and not well known. PTP1B is also regulated by sumoylation 
in the last two lysine residues of the C-terminus by SUMO E3 PIAS1 
(ligase protein inhibitor of activated STAT-1) (66). This post-translational 
modification is associated with a reduction in enzymatic activity. 
Proteolysis plays another important part in the activation and in the 
inactivation of PTP1B. The cleavage of the C-terminus domain by calpain-
1 is required for its activation, interestingly the oxidized PTP1B form is the 
cleavage in small inactivate fragments (67-69). 
Early studies showed PTP1B as a negative regulator of insulin and leptin 
signaling pathways. Recent studies have revealed that PTP1B has a positive 
role in tumorigenesis. Infact, PTP1B acts as a positive regulator of Src in 
breast cancer, dephosphorylating the inhibitory Y529 site, thereby 
activating this kinase (53) (54). In the insulin pathway, PTP1B 
dephosphorylates the insulin receptor (IR) as well as the IRS proteins (55), 
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furthermore in the leptin signaling the regulation is through the 
dephosphorylation of the tyrosine kinase JAK2 (Janus kinase 2) (56). 
                                                                                                                
Yip SC. 2010 
Figure 8. Structural representation of PTP1B domain. PTP1B is a protein of 
435 amino acids composed by different domain. At N-terminal is present the 
catalytic domain (green) at C-terminal the ER targeting domain (orange), 
bordering two proline-rich domains (PRD: 278-401AA; purple), which are crucial 
for protein–protein interactions. 
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2. Aim of the Study  
Protein tyrosine phosphatase 1B (PTP1B) is implicated as a negative 
regulator of the Insulin and Leptin pathways, controlling the correct 
activation and propagation of the signal transduction inside the cell. 
Ubiquitination is a post-translational mechanism that controls the activity 
and the stability of wide number of proteins, regulating key physiological 
processes, such as survival, differentiation and cell proliferation (15, 16, 
70). 
In the last years, the research line of our laboratory was focused on the 
regulation of different biological events elicited by the E3 ubiquitin ligase 
praja2. During my PhD program, I focused my attention on identifying and 
characterizing a novel interactor of praja2, namely PTP1B. The impact of 
such a regulation on metabolic pathway was the key issue. Below are the 
principal aims: 
● Analyze the role of praja2 in the insulin pathway and identify its 
relevant target (PTP1B). 
● Characterize praja2/PTP1B complex in cells. 
● Test if praja2 ubiquitinates PTP1B and how this impact on the 
downstream pathway. 
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3. Materials and Methods  
 
3.1 Cell lines. Human embryonic kidney cell line (HEK293) 
 were cultured in DMEM containing 10% fetal bovine serum (FBS) 
supplemented with 2mM L-glutamine, 100 IU/ml penicillin, in an 
atmosphere of 5% CO2 at 37°C.  
 
3.2 Plasmids, siRNAs and transfection. Vectors encoding for flag-praja2 
(wild type) were purchased from Genecopeia. Flag-praja2rm and Flag-
praja2 mutants were generated by site-directed mutagenesis (GenScript), 
whereas praja2-deletion mutants were generated by PCR with specific 
oligonucleotide primers and subcloned into the same vector of wild-type 
praja2 cDNA. Myc-Ub, were provided by Dr Carlomagno F. Vectors 
encoding for PTP1B-HA and PTP1B-GST were purchased from addgene 
(nonprofit plasmid repository).    
 siRNAs were transiently transfected using Lipofectamine 2000 
(Invitrogen) at a final concentration of 100 pmol/ml of culture medium. For 
siRNA experiments, similar data were obtained using a mixture or four or 
two independent siRNAs. Transfection efficiency was monitored by 
including a GFP vector in the transfection mixture. Below are there  the 
siRNA sequences (Thermo Scientific; LU-006916-00-10) targeting human 
praja2: 
Sequence 1: 5′-GAAGCACCCUAAACCUUGA-3′; 
Sequence 2: 5′-AGACUGCUCUGGCCCAUUU-3′; 
Sequence 3: 5′-GCAGGAGGGUAUCAGACAA-3′; and  
Sequence 4: 5′-GUUAGAUUCUGUACCAUUA-3′. 
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3.3 Antibodies and chemicals. Monoclonal antibody directed against 
PTP1B were purchased from Millipore Merck and used at working 
concentration of 1:1000. Rabbit Praja2 were purchased from Bethyl 
Laboratories, mouse GST, Actin and ERK1 from Santa Cruz 
Biotechnology. Polyclonal antibodies directed against GSK3β, p- GSK3β, 
S6K and p-S6K were purchased from Cell Signaling.  
Monoclonal antibodies directed against flag and myc epitope used at 
working diluition 1:3000 were purchased from Sigma. PTP1B XXII 
Inhibitor were purchased from Millipore Merck. Forskolin and Insulin 
were purchased from Sigma. 
 
3.4 Immunoprecipitation and pull down assay. Cells were washed twice 
with phosphate-buffered saline and lysed in a buffer (50mM TRIS–
hydrogen chloride, pH 7.4, 150mM sodium chloride, 5mM magnesium 
chloride, 5mM dithiothreitol, 1mM ethylene diamine tetraacetic acid, 1% 
Triton X-100,containing aprotinin (5 g/ml), leupeptin (10 g/ml), 
pepstatin (2 g/ml), Na3VO4 and 1mM phenylmethylsulfonyl fluoride and 
protease inhibitors. The lysates were cleared by centrifugation at 15,000 g 
for 15 min. Cell lysates (2 mg) were immunoprecipitated in rotation at 4 °C 
overnight with the indicated antibodies. Pellets were washed four times in 
lysis buffer and eluted in Laemly buffer. An aliquot of whole cell lysates 
(WCE) (100 g) or immunoprecipitates were resolved on sodium dodecyl 
sulfate polyacrylamide gel and transferred on nitrocellulose membrane 
using iBLOT2 technology from Thermo Fisher Scientific. Filters were 
blocked for 1 hour at room temperature in Tween-20 Phosphate buffer 
saline (TPBS) (PBS- Sigma, 0, 1% Tween 20, pH 7.4) containing 5% 
nonfat dry milk. Blots were then incubated O/N with primary antibody. 
Blots were washed three times with TPBS buffer and then incubated for 1 
hour with secondary antibody (peroxidase-coupled anti rabbit (GE-
Healthcare) in TPBS. Reactive signals were revealed by enhanced ECL 
Western Blotting analysis system (Roche).  
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GST-fusions were expressed and purified from BL21 (DE3) pLysS cells. 
GST hybrid proteins immobilized on glutathione beads were incubated for 
3 hours with cell lysates from HEK293 cells transiently expressing praja2-
rm-FLAG and mutants constructs in lysis buffer (150 mM NaCl, 50 mM 
Tris-HCl pH 7.5, 5mM MgCl2, 5mM DDT, 1 mM EDTA, 1% triton X-100) 
in rotation at 4 °C for 4 hours. Pellets were washed four times in lysis buffer 
supplemented with NaCl (1 M final concentration) and eluted in Laemmli 
buffer. Eluted samples were size-fractionated on SDS-PAGE and 
immunoblotted. 
 
3.5 Immunofluorescence and confocal analysis. For immunofluorescence 
studies, HEK293 cells were plated on poly-L-lysine (10µg/ml) coated glass 
coverslips. Cells were fixed with Paraformaldehyde for 20 minutes. After 
three washes, cells were immunostained with polyclonal antibody directed 
against praja2 (Betyl) used at working dilution of 1:50, or with monoclonal 
antibody directed against PTP1B (Millipore Merck) and used at working 
dilutions of 1:100. High-resolution images were acquired with a Zeiss LSM 
880 confocal microscope equipped with Airyscan super-resolution imaging 
module, using a 63×/1.40 NA Plan-Apochromat Oil DIC M27 objective 
lens (Zeiss MicroImaging, Jena, Germany)  
 
3.6 Statistics. Data were analyzed using analysis of variance (ANOVA) for 
each region and post hoc repeated-measure comparisons (Least Significant 
Difference (LSD) test). Rejection level was set at P < 0.05. 
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4. Results 
4.1. Identification of PTP1B as a novel praja2 interacting partner. 
In our previous studies, we demonstrated the important role of praja2 in the 
regulation of several intracellular pathways (29-31, 33). Given the 
importance of this E3 ligase in the cell homeostasis and physiology, I 
decided to investigate the role of praja2 in cell metabolism. Specifically, I 
analyzed whether praja2 regulates insulin signaling. As readout, I 
monitored the phosphorylation of GSK3β at serines 9/21, a well known 
insulin regulated kinase. I transfected HEK293 cells with a vector encoding 
for a dominant negative mutant of praja2, called praja2-rm. The mutant 
protein is characterized by point mutations in the RING-H2 domain 
(C634/671A). Praja2-rm binds its substrates but it is not able to transfer the 
ubiquitin molecules on them, acting as a dominant inactive mutant towards 
the endogenous protein. Cells were treated with insulin (10 µM) for 15, 30, 
45 minutes, then were harvested and lysates subjected to western blot assay 
Fig.9. The experiments in Fig.9 show that cells transfected with praja2-rm 
vector displayed a decreased insulin-stimulated phosphorylation of GSK3β 
compared to control cells. This finding suggested that praja2 is, indeed, 
involved in the regulation of the insulin signaling.  
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Figure 9. praja2-rm mutant inhibits GSK3β phospshorylations. HEK293 
were transiently transfected with an empty vector (CMV) or with a vector 
encoding for praja2 RING mutant (C634, 671A; praja2-rm). Cells were serum 
deprived overnight, and then treated with insulin (10 µM) at indicated times. 
Lysates were separated on SDS-page and immunoblotted with anti-GSK3β and 
anti- pGSK3β. 
 
 
 
Impairment of insulin signaling by praja2 inactive mutant suggested that a 
negative regulator of the insulin signaling could be a target of praja2. To 
identify this praja2 target, I looked for complexes between praja2 and 
different well known negative regulators of the insulin pathway, like PP2A, 
PTEN or PTP1B (data not shown). Using specific antibodies, I performed 
co-immunoprecipitation experiments using lysates from HEK293 cells. 
Among the potential partners analyzed, I found PTP1B as a novel praja2 
interactor. (Fig 10A). To support the co-immunoprecipitation data, I 
performed pull-down experiments using purified recombinant GST-PTP1B 
fusion protein on HEK293 lysates expressing praja2-rm. The GST-
precipitates were immunoblotted with anti-Flag and anti-GST antibodies. 
This experiment confirmed that praja2 binds PTP1B (Fig 10B). I used 
GST-beads as negative control. 
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Figure 10. praja2 binds PTP1B. (A) HEK293 lysates were immunoprecipitated 
(IP) with anti-PTP1B or with control IgG. The precipitates and an aliquot of 
lysates (EXT) were immunoblotted with anti-praja2 and anti-PTP1B antibodies. 
(B) HEK293 cells were transiently transfected with praja2 RING mutant (praja2-
rm) and lysed. Total lysates were subjected to pull down assay with beads linked 
to GST-PTP1B recombinant protein or GST as control. Precipitates and aliquot 
of the lysates were immunoblotted with anti-Flag and anti-GST antibodies.   
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Next, to demonstrate that PTP1B and praja2 are located within the same 
subcellular compartment, I performed an immunofluorescence experiment 
using anti-PTP1B and anti-praja2 antibodies in formalin-fixed HEK293 
cells. The results indicate that praja2 and PTP1B partly colocalized within 
the endoplasmic reticulum and perinuclear region, as shown by the 
Pearson’s coefficient analysis (Fig.11)   
 
Figure 11. praja2 and PTP1B partly co-localize in cells. (A) HEK293 cells 
were subjected to double immunostaining with anti-PTP1B and anti-praja2 
antibodies. Images were analyzed and collected by confocal microscopy. 
Magnification of selected areas is shown (insets). A Pearson’s coefficient praja2-
PTP1B was calculated: 0.52. Scale bar: 5µm. 
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4.2 Identification of the PTP1B-binding domain on praja2 
The next step was to identify the PTP1B binding site on praja2. Therefore, 
we generated three praja2 deletion mutants at the C-terminus region, using 
as template flag-praja2 (praja21-630 Flag, praja21-530 Flag and praja21-401 
Flag) and tested the ability of these mutants to bind PTP1B. I transfected 
HEK293 cells with praja2-rm or praja2 deletion mutants described above 
and performed co-immunoprecipitation assays. Lysates were 
immunoprecipitated with anti-Flag antibody and immunoblotted with anti-
Flag and anti-PTP1B antibodies. As Fig.12 shows, praja21-401 mutant was 
not able to bind PTP1B, while praja21-530 was, suggesting that the residues 
between 401-529 of praja2 are required for PTP1B binding. 
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Figure 12. Identification of PTP1B binding domain on praja2. Schematic 
representation of human praja2 and its deletion mutants. RING domain and 
PTP1B binding domain are shown in green and in yellow (upper panel), 
respectively. HEK293 cells were transfected with praja2 RING mutant (praja2-
rm), or with each of the three deletion mutants (praja2 1-630 Flag, praja2 1-530 
Flag, and praja2 1-401 Flag). Lysates from transfected cells were 
immunoprecipitated with anti-flag antibody. The precipitates and aliquot of the 
lysates (EXT) were immunoblotted with anti-Flag and anti-PTP1B antibodies.  
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To further prove that the region spanning residues 401-529 of praja2 is, 
indeed, required to bind PTP1B, I generated a praja2 deletion mutant 
lacking residues 401-530 (praja2-∆ptp1b Flag), and tested its ability to 
interact with PTP1B by pull down and co-immunoprecipitation assays. 
HEK293 were transiently transfected with praja2-rm or praja2-∆ptp1b 
vector and harvested. Total lysates were subjected to pull down assay using 
GST-PTP1B or GST as control. Precipitated complexes were washed three 
times using 1M NaCl lysis buffer and immunoblotted with anti-Flag and 
anti-GST antibodies. The results shown in Fig.13A indicate that praja2-
∆ptp1b mutant does not bind PTP1B. Next, I performed co-
immunoprecipiation assays using lysates prepared from HEK293 cells 
transiently transfected with praja2-rm, praja2-∆ptp1b or PTP1B-HA 
vectors. The epitope-tagged praja2 variants were immunoprecipitated with 
anti-Flag antibody. Immunoprecipates were immunoblotted with anti-Flag 
and anti-HA antibodies. The results assay confirmed that residues 401-530 
of praja2 are required for PTP1B binding (Fig.13B). 
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Figure 13. Praja2 deletion mutant Praja2-∆ptp1b Flag (401-531) does not 
bind PTP1B. Schematic representation of human praja2 and its deletion mutants. 
RING domain and PTP1B binding domain are shown in green and in red (upper 
panel), respectively. (A) HEK293 cells were transfected with praja2 RING mutant 
(praja2-rm), or with pja2-∆ptp1b Flag (401-531) vector. Lysates from transfected 
cells were subjected to pull down assays with GST-PTP1B recombinant protein 
or with GST beads. The precipitates and an aliquot of lysates (EXT) were 
immunoblotted with anti-Flag and anti-GST antibodies. (B) HEK293 cells were 
transiently co-transfected with praja2 RING mutant (praja2-rm), or with praja2-
∆ptp1b Flag (401-531) and PTP1B-HA vectors. Lysates were immunoprecipitates 
(IP) with anti-Flag antibody. The precipitates and an aliquot of the lysates were 
immunoblotted with anti-FLAG and anti-HA antibodies 
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4.3 PTP1B is ubiquitinated by praja2 
The data indicate that PTP1B is a novel interactor of praja2. Since praja2 
is an E3 ubiquitin ligase, I tested if PTP1B is also a substrate of praja2. For 
this purpose, I monitored the linkage of ubiquitin chain to PTP1B in cells 
expressing PTP1B-HA, myc-tagged ubiquitin and praja2 or praja2-rm. 
PTP1B was immunopurified from total cell lysates with anti-HA antibody. 
The precipitates were immunoblotted with anti-Myc, anti-HA and anti-
Flag antibodies. The data show that overexpression of praja2, but not of its 
inactive mutant (praja2-rm), induced accumulation of polyubiquitinated 
forms of PTP1B (Fig.14A). Given the role of PTP1B in the regulation of 
insulin signaling, I analyzed the effects of insulin stimulation on PTP1B 
polyubiquitination. As shown in Fig.14B, one hour stimulation with insulin 
was sufficient to induce PTP1B polyubiqutination. The effects of insulin 
were abrogated by expressing the praja2 inactive mutant (praja2-rm), 
supporting a role of endogenous praja2 in mediating PTP1B 
polyubiquitination.  
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Figure 14. praja2 ubiquitinates PTP1B. (A) HEK293 cells were co-transfected 
with Myc-tagged ubiquitin and praja2 RING mutant (praja2-rm) praja2-wt Flag 
vectors. Lysates were immunoprecipitates (IP) with anti-HA antibody and 
immunoblotted with anti-Myc and anti-FLAG antibodies. (B) HEK293 cells were 
co-transfected with Myc-tagged ubiquitin, praja2 RING mutant (C634, 671A; 
praja2-rm) and an empty vector. After 24 hours of transfection cells were serum 
deprived for 12 hours, cells either were left untreated or stimulated with insulin 
(10 µM) at indicated time. Lysates were immunoprecipitates (IP) with anti-HA 
antibody and immunoblotted with Anti-Myc, anti-FLAG and anti-HA antibodies. 
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4.4 praja2 promotes PTP1B degradation by the proteasome. 
praja2 is involved in the poly ubiquitination of PTP1B. The next step was 
to understand if polyubiquitination of PTP1B was linked to its proteasomal 
degradation.  HEK293 cells were transfected with praja2-Flag or with 
praja2-rm-Flag and then treated with MG132 (10uM) (a proteasome 
inhibitor) for six hours. Cells were harvested and lysed. Lysates were 
immunoblotted with anti-Flag, anti-PTP1B and anti-ERK2 antibodies. The 
latter was used as loading control. The results show that expression of 
praja2, but not of its inactive mutant (praja-rm), caused a decrease of 
PTP1B levels that was prevented by the treatment with MG132, suggesting 
that the proteasome mediate praja2-dependent PTP1B degradation (Fig 
15). 
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Figure 15. praja2 promotes PTP1B degradation through the proteasome 
degradation. HEK293 cells were transfected with an empty vector, praja2-wt 
Flag or with praja2 RING mutant (Praja2-rm) vector. Cells were left untreated or 
treated with MG132 (10 µM) for 6 hours before harvesting. Lysates were 
immunoblotted with anti-Flag, anti-PTP1B and anti-ERK2 antibodies. Lower 
panel shows cumulative data expressed as a mean value ± S.E.M of three 
independent experiments. 
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4.5 cAMP-praja2 axis regulates PTP1B Stability 
Previous works demonstrated that praja2 acts in response to cAMP to 
ubiquitinate and degrade a variety of intracellular targets (29-31, 33). 
Accordingly, I analyzed the effects of cAMP stimulation on PTP1B 
stability. For this pupose, HEK293 cells were serum deprived overnight, 
treated with Forskolin (40µM), a potent agonist of the adenylyl cyclase, 
and harvested at different times from stimulation (0 30’ 60’ 90’ 120’). 
Results shown in Fig.16 indicate that stimulation of cAMP signaling 
decreased the levels of PTP1B.  
Next, I analyzed the contribution of praja2 in cAMP-induced decrease of 
PTP1B by performing a genetic knockdown of endogenous praja2 by an 
RNAi procedure. Thus, HEK293 cells were transiently transfected with 
siRNAs targeting endogenous praja2 or with control siRNAs. Following 
transfection, cells were serum deprived overnight and then treated with 
Forskolin (40µM) (0, 30’, 60’, 90’, 120’) as above. Lysates were 
immunoblotted with the indicated antibodies. Fig. 17 shows that 
downregulation of praja2 by siRNAs efficiently prevented PTP1B 
degradation induced by the Forskolin treatment, promoting accumulation 
of the phosphatase at each time point of forskolin treatment, compared to 
controls. Altogether, these findings demonstrate that praja2 is an important 
regulator of PTP1B stability, constituting a nodal point where insulin and 
GPCR-cAMP pathways may converge and focus to control downstream 
metabolic pathways. 
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Figure 16. cAMP regulates PTP1B stability. Cells were serum deprived for 24 
hours and then treated with Forskolin (40µM) at indicated time points. Lysates 
were immunoblotted with anti-PTP1B and anti-ERK1 antibodies. Lower panel 
shows cumulative data expressed as a mean value ± S.E.M of three independent 
experiments. *P<0.05 versus control. 
  
39 
 
 
 
 
Figure 17. cAMP regulates PTP1B stability through praja2. HEK293 cells 
were transfected with control siRNA or with siRNA targeting praja2. Transfected 
cells were serum deprived overnight and then treated with forskolin (40µM) for 
the indicated time points. Lysate were immunoblotted with anti-PTP1B, anti-
praja2 and anti-actin (loading control) antibodies. Lower panel shows cumulative 
data expressed as a mean value ± S.E.M of three independent experiments. 
*P<0.05 versus control. 
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4.6 Praja2 regulates insulin signaling.  
The findings above indicate that praja2 regulates PTP1B stability. PTP1B 
is a negative regulator of the insulin signaling (71, 72). Accordingly, I 
tested the role of praja2 in the activation of the insulin pathway, focusing 
on p70S6Kinase. HEK293 cells were transfected with praja2-rm. 24 hours 
after transfection, cells were treated with insulin (10µM) at indicated times 
(0 15’ 30’ 45’), harvested and lysed.  Lysates were subjected to 
immunoblot analysis with anti-p70S6K, anti-70S6K and anti-flag 
antibodies. The results in Fig.18A show that praja2 inactive mutant 
(praja2-rm) caused an impairment of insulin-induced p70S6K 
phosphorylation. I performed similar experiments by knocking down 
endogenous praja2 (Fig.18B). The results supported the role of praja2 in 
regulating insulin-dependent phosphorylation of p70S6K. 
Finally, to prove that praja2 acts through protein phosphatases in 
modulating insulin signaling, I repeated the experiments above by 
pretreating the cells with PTP1B XXII, a selective, reversible and non-
competitive allosteric inhibitor of PTP1B. Fig. 19 shows that the treatment 
with PTP1B XXII rescued the effect of praja2 genetic knock down on 
p70S6K phosphorylation. 
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Figure 18. praja2 regulates phosphorylation of p70S6Kinase. (A) HEK293 
cells were transfected with an empty vector or with praja2 RING mutant (praja2-
rm) vector. Transfected cells were serum deprived overnight and then treated with 
insulin (10 µM) for the indicated time points. Lysates were immunoblotted with 
anti-Flag, anti-p70S6K and anti-70S6K antibodies. (B) HEK293 were transfected 
with control siRNA or praja2 SiRNA. Lysate were separated on SDS-page and 
immunoblotted with anti-praja2, anti-p70S6K and anti-70S6K antibodies.  
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Figure 19. Praja2 is required for GSK3β phosphorylation. HEK293 cells were 
transfected with control siRNA or praja2 SiRNA. Transfected cells were then 
serum deprived overnight, pretreated (+) or not (-) with PTP1B XXII inhibitor 
(10µM) for 30’ and then stimulated with insulin (10 µM) for 30 minutes. . Lysate 
were separated on SDS-page and immunoblotted with anti-p70S6K and anti-
70S6K antibodies. 
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5. Discussion 
PTP1B emerged as a crucial protein in cell signaling and a potential target 
for metabolic diseases, such as type II diabetes, obesity and cancer. PTP1B 
could be regulated at different levels by mechanisms involving oxidation, 
phosphorylation and sumoylation (59, 64, 65, 67-69, 73). However, the role 
of the ubiquitin pathway in the control of PTP1B stability and signaling 
was still unknown. Here, I’ve identified a new regulatory mechanism that 
efficiently couples the ubiquitin/proteasome system to the insulin cascade 
that involves the E3 ubiquitin ligase praja2. I’ve found that praja2 interacts 
with- and regulates the stability of PTP1B, modulating its ubiquitination 
and stability, and exerts major effects on the insulin pathway. 
The ubiquitin proteasome system (UPS) has emerged as an important 
control mechanism of cell growth, survival and metabolism. Degradation 
of a protein via UPS involves modification of the substrate protein by 
covalent attachment of multiple ubiquitin molecules (70, 74). The 
ubiquitin-tagged protein is eventually degraded by the proteasome. By 
modulating the levels of target proteins, the UPS controls essential aspects 
of cell biology. Emerging evidence indicates that changing in the levels, 
subcellular targeting and catalytic activity of the E3 ubiquitin ligases, 
enzymes involved in the ubiquitination of UPS targets, may exert major 
effects on metabolism, tumor cell growth and survival (75). The UPS is 
strongly involved in the correct homeostasis of the skeletal muscle. Thus, 
the E3 ubiquitin ligase Thatmuscle-specific mitsugumin 53 (MG53) 
regulates the insulin receptor and IRS1 protein stability through the 
ubiquitin pathway (80). MG53 overexpression is observed in several 
animal models and in obese humans. MG53 up-regulation is strongly 
related to the insulin resistance in skeletal muscle, which is responsible for 
70–90% of insulin-stimulated glucose disposal (80).  
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Cell growth and senescence are crucial aspects of cellular homeostasis that 
are regulated and controlled by the UPS. Thus, Cullin 7 (CUL7) E3 
ubiquitin ligase complex directly regulates the insulin pathway through the 
control of IRS-1 stability, constituting a relevant feedback control 
mechanism of mTOR/S6K pathway (87). Dysregulation of this signaling 
network leads to cell senescence, possibly through sustained MAPK 
activation and/or increased Akt signaling (87, 91, 92). Therefore, 
identification of the targets and effectors of UPS pathway and 
understanding the basic mechanism(s) governing protein stability represent 
important goals for the design of effective drugs for metabolic diseases and 
cancer.  
Praja2 belongs to a growing family of widely expressed mammalian 
RING-H2 proteins with intrinsic E3 ubiquitin-ligase activity and plays an 
important role in different aspects of cell physiology (29, 34). Praja2 acts 
as an AKAP that binds and targets PKA holoenzyme to the cell membrane, 
perinuclear region and cellular organelles. Co-localization of praja2•PKA 
complexes with PKA substrate/effector molecules ensures efficient 
integration and propagation of the locally generated cAMP to distinct 
target sites. By regulating cAMP signaling, praja2 efficiently couples 
phosphorylation to ubiquitination of protein kinases, scaffolds and 
effectors, with important implication for differentiation and cell 
proliferation. Dysregulation of praja2-regulated signaling has been 
causally linked to GBM growth and progression (31). 
Here, I report that PTP1B is a novel partner of praja2. PTP1B represents a 
crucial protein in the study of metabolic diseases such as type II diabetes, 
but it is emerging, also, as a controversial partner in cancer development. 
 Several studies define PTP1B as negative regulator of cell growth and cells 
transformation. Thus, PTP1B has inhibitory effects on many RPTKs and it 
is involved in cell–cell adhesion promoting N-cadherin–β-catenin complex 
formation (100-102). In addition, PTP1B contributes to apoptotic cascade 
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enhancing IRE1-mediated ER stress signaling, as well as by 
dephosphorylating STAT3 during TRAIL-induced apoptosis (102-104).  
PTP1B is also involved in the regulation of bone marrow cells. In this 
context, myeloid-specific deficiency of PTP1B is sufficient to promote the 
development of acute myeloid leukemia (AML) (105). Controversially, in 
many tumors PTP1B protein levels are increased, especially in breast and 
ovary cancer (102, 106, 107). Indeed, over-expression of PTP1B has an 
oncogenic role in ErbB2+ breast cancer, modulating Src Y529 
phosphorylation and Src-related signaling pathways (108). In the same 
way, PTP1B regulates positively cell proliferation and metastasis in non-
small cell lung cancer, as much as in gastric cancer (109, 110). 
In light of the role of PTP1B in important pathways involved in cell 
metabolism and proliferation, it became critical to study and understand 
how PTP1B is regulated. Different types of post-translational 
modifications are entailed in PTP1B modulation, such as: reversible 
oxidation (59), serine and tyrosine phosphorylations (62, 63)(64)(65), 
sumoylation by SUMO E3 PIAS1 (ligase protein inhibitor of activated 
STAT-1) (66) and proteolysis (67-69). In my thesis, I report a new 
mechanism of post-translational modifications of PTP1B, based on the 
ubiquitination and proteolysis of the phosphatase by the UPS. 
Biochemical experiments demonstrated that praja2 interacts with PTP1B. 
Deletion mutagenesis and in vitro binding assays identified the domain 
spanning residues 400-530 of praja2 as responsible of PTP1B binding. This 
domain is just upstream the region of praja2 that mediates the interaction 
to other signaling proteins, as PKA and MOB1 (29, 31). However, if and 
how the binding of PT1B to praja2 affect interaction with other signaling 
relays needs further analysis. 
Previous work demonstrated that direct phosphorylation of praja2 by PKA 
induces its E3 ligase activity. Thus, following cAMP stimulation, several 
praja2 partners undergo to extensive ubiquitination and subsequent 
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proteolysis through the proteasome, with important biological 
consequences on downstream signaling pathways involved in cell growth 
and differentiation. Similarly, I found that praja2 ubiquitylates and 
degrades PTP1B. The proteolysis of PTP1B can be induced by cAMP 
stimulation and it is mediated by praja2. This finding suggested that praja2 
by modulating the ubiquitination and stability of PTP1B can elicit major 
effects on PTP1B-regulated signaling pathways. To prove this hypothesis, 
I analyzed the effects of praja2 downregulation on insulin pathway. In 
particular, I used two distinct approaches, such as genetic knockdown of 
praja2 or expression of dominant negative variants of praja2. In both 
experimental conditions, I found that, interfering with praja2 expression or 
activity, the phosphorylation of two relevant metabolic targets of the 
insulin pathway (GSK3b and p70S6K), is impaired. This strongly 
suggested that praja2, beyond its role in cell growth and differentiation, is 
also implicated in the key aspects of metabolic pathways regulated by 
insulin.  
Another important observation that emerged from my studies relates to the 
cross-talk between GPCR-cAMP signaling and the insulin pathway. I 
found that cAMP stimulation promotes a rapid and transient degradation of 
PTP1B by the praja2-UPS pathway. Removing a negative regulator of the 
insulin pathway, such as PTP1B, GPCR signaling may contribute to sustain 
the insulin-dependent metabolic pathways. To formally prove that praja2 
regulates metabolic pathways in vivo, we have generated an inducible 
praja2 knock out mouse line. The analysis of KO mouse line will reveal the 
role of praja2 in such metabolic pathways. 
Collectively, the data reported in the thesis suggest a model (Fig. 20) 
whereby, as consequence of GPCR-cAMP, PTP1B undergoes to praja2-
dependent ubiquitination and proteolysis through proteasome. By 
removing PTP1B, cAMP-praja2 axis positively regulates the transmission 
of insulin signals to downstream metabolic targets. This represents a novel 
point of intersection between both GPCR and insulin pathways, with 
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important implications in cell physiology. The molecular characterization 
of praja2-regulated signaling pathways, the generation of appropriate 
animal models of praja2 knockout and the identification of genetic 
mutations affecting praja2 function in vivo, will likely provide novel 
therapeutic targets for the treatment of human metabolic and proliferative 
disorders.  
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Figure 20. Working model. Schematic representation of PTP1B stability in the 
insulin cascade. Propagation of the cAMP waves and activation of the insulin 
receptor by its ligand leads to PTP1B ubiquitination by praja2 and its consequent 
degradation by the proteasome. Downregulation of PTP1B levels by praja2 would 
enhance the sensitivity of the insulin cascade to hormone stimulation.     
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6. Appendix 
 
IR: Insulin Receptor  
IGF-1: Insulin-like growth factor 
GPCRs: G protein–coupled receptors  
AD: Adenylate cyclase 
cAMP: Cyclic-AMP 
PDE: Phosphodiesterase 
PKA: Protein Kinase A 
GST: Glutathione S-transferase  
FSK: Forskolin  
mTOR: Target of rapamycin 
GSK3β: Glycogen synthase kinase 3 beta 
S6K: Ribosomal protein S6 kinase beta-1  
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